| KAOHSIUNG MEDICAL UNIVERSITY Patent applications |
| Patent application number | Title | Published |
|---|
| 20130137597 | Microrna-based method for anti-colorectal cancer effects and prognosis of colorectal cancer - The present invention discloses a method of providing anti-oncogenic effects in a subject suffered from colorectal cancer. The present invention also discloses a method for screening an anti-colorectal cancer agent. The present invention further discloses a method of determining the prognosis of a subject with colorectal cancer. | 05-30-2013 |
| 20130136714 | FUNCTIONALIZED POLYMER NANOPARTICLES AND THE PHARMACEUTICAL USE THEREOF - PEO-PPO-PEO polymers and vinyl monomers are used to prepare several block copolymers via consecutive atom transfer radical polymerization (ATRP). The block copolymers provide good delivery characteristics and can be used as a gene/drug delivery carrier for therapy and diagnosis. | 05-30-2013 |
| 20130123544 | COMPOSITION AND GINGER EXTRACT FOR PROMOTING PROLIFERATION AND/OR MIGRATION OF SKIN CELLS, AND PHARMACEUTICAL COMPOSITION USING THE SAME - A composition for promoting proliferation and/or migration of skin cells includes a compound of formula (I): | 05-16-2013 |
| 20130122110 | ANTI-HUMAN UROTHELIAL CARCINOMA OF SUPERCRITICAL CARBON DIOXIDE EXTRACT OF CINNAMOMUM SUBAVENIUM, AND THE PREPARATION PROCESS AND USES - What is disclosed in the invention is a preparation method of a supercritical | 05-16-2013 |
| 20130096018 | METHOD FOR PREDICTING THE SURVIVAL STATUS AND PROGNOSIS OF ESOPHAGEAL CANCER AND A KIT THEREOF - The present invention provides a method for predicting the survival rate and prognosis of esophageal carcinoma patients, which is characterized in examining the expression level of a specific gene, peptidase inhibitor 3 (PI3) or CD14 antigen (CD14) in a sample, and comparing to the average expression level of said specific gene from patients to determine the survival and prognosis status for esophageal cancer. The present invention further provides a kit for predicting the survival rate and prognosis of esophageal carcinoma patients. | 04-18-2013 |
| 20130095059 | INHALED NO DONOR KMUPS DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION VIA SUPPRESSED CYTOKINES, INOS AND INFLAMMATORY CELL COUNTS IN ASTHMA MODEL - A method for treating a disease is provided. The method includes steps of: providing a subject in need thereof; and administering one selected from a group consisting of KMUPS compound represented by formula I, a pharmaceutically acceptable salts thereof; and a pharmaceutical composition thereof to the subject in a dosage from 1 to 2.5 milligram per kilogram of body weight, | 04-18-2013 |
| 20130089601 | METHOD FOR TREATING ATHEROSCLEROSIS - The invention provides a method for treating atherosclerosis in a subject in need thereof, including administering an effective amount of microRNA-195 to the subject in need thereof. The microRNA-195 may be packaged in a pharmaceutically acceptable carrier. Moreover, the pharmaceutically acceptable carrier may includes a liposome, lipid particle or viral vector. | 04-11-2013 |
| 20130072694 | 18 -GLYCYRRHETINIC ACID DERIVATIVES AND SYNTHETIC METHOD THEREOF - The present invention provides a chemical compound having the structure being one selected from a group consisting of | 03-21-2013 |
| 20130067605 | hnRNP A1 KNOCKOUT ANIMAL MODEL AND USE THEREOF - A nucleic acid construct comprising a genetic engineered heterogeneous nuclear ribonucleoprotein (hnRNP) A1 gene is provided. A transgenic mouse in which the expression of hnRNP A1 gene has been disrupted is also provided. The mouse is useful for studying the role of hnRNP A1 gene in normal and disease states of a neurodegenerative disease or a cancer for developing therapies to treat any of these diseases. Therefore, a method of screening a compound for potential use in prevention and/or treatment of neurodegenerative disease or cancer is further provided. | 03-14-2013 |
| 20130053699 | APPARATUS AND METHOD FOR PERFORMING PHOTODYNAMIC DIAGNOSIS AND PHOTODYNAMIC THERAPY - An apparatus for performing photodynamic diagnosis and photodynamic therapy on a target region that is pre-given with a photosensitizer precursor includes a display unit, an excitation light source operable to irradiate the target region with exciting light so as to excite emission of fluorescence from the target region as a result of fluorescence response of the photosensitizer precursor, an image capturing unit operable to capture a white light image and a fluorescent image of the target region, an image processing unit operable to superimpose the white light image and the fluorescent image into a synthesized image and to provide at least one of the white light image, the fluorescent image and the synthesized image thereto for display on the display unit, and a curing light source operable to irradiate a specified portion of the target region with curing light for treating the specified portion. | 02-28-2013 |
| 20130040996 | COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF - Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL). | 02-14-2013 |
| 20130030119 | POLYSACCHARIDE-GRAFTED POLYETHYLENIMINE AS A GENE CARRIER - The present invention discloses a gene carrier and the preparation method thereof. Chondroitin sulfate (CS) is reacted with methacrylic anhydride (MA) to form chrondroitin sulfate-methacrylate (CSMA), which is further covalently bound with polyethylenimine (PEI) via the Michael addition to produce a CSMA-PEI gene carrier. The CSMA-PEI gene carrier can effectively reduce the cytotoxicity of PEI and enhance the transfection efficiency of PEI. | 01-31-2013 |
| 20120329853 | MICRORNA-BASED METHOD FOR ANTI-COLORECTAL CANCER EFFECTS AND PROGNOSIS OF COLORECTAL CANCER - The present invention discloses a method of providing anti-oncogenic effects in a subject suffered from colorectal cancer. The present invention also discloses a method for screening an anti-colorectal cancer agent. The present invention further discloses a method of determining the prognosis of a subject with colorectal cancer. | 12-27-2012 |
| 20120321584 | PROCESSES FOR PREPARING AMINE SALTS OF KMUP-3 AND USE THEREOF - An inhibiting heart failure disease pharmaceutical composition is provided.
| 12-20-2012 |
| 20120283475 | SYNTHESIS AND ANTITUMOR ACTIVITY OF NOVEL BIS(BENZYLIDENE-BENZENAMINE)DISULFIDES - Novel synthetic bis(benzylidene-benzenamine)disulfides and the preparation method are disclosed in the present invention. These compounds are afforded with the oxidizing reagent at low temperature and short time period via intra-molecular coupling reaction. In vitro experiments have been revealed that bis-disulfides are cytotoxic to cancer cells, especially human breast cancer cells MCF-7. Additionally, bis-disulfides arrest the cell cycle at sub-G1 phase and increase p38 phosphorylation to result in apoptosis. Bis-disulfides also inhibit growth of murine melanoma B16 cells but have no cytotoxicity to human fibroblasts. Bis-disulfides also can reduce murine melanoma size in the mouse model. The prepared compounds of the invention would be applicable in anti-cancer and anti-tumor therapies. | 11-08-2012 |
| 20120270811 | CONFORMATIONS OF DIVERGENT PEPTIDES WITH MINERAL BINDING AFFINITY - A series of peptides with divergent confirmations including structures of formula (1A), (1B), (2) and (3) are provided. In the formula, wherein U, G, A, B, R1, R2 and T are as defined in the specification. The divergent peptides disclosed in the present invention are characterized in a mineral binding affinity function. | 10-25-2012 |
| 20120264830 | CHONDROITIN SULFATE-POLYCAPROLACTONE COPOLYMER, METHOD FOR PREPARING THE SAME AND APPLICATION THEREOF - A method for preparing a chondroitin sulfate-polycaprolactone copolymer includes subjecting a chondroitin sulfate component and a polycaprolactone polymer to an atom transfer radical polymerization reaction in the presence of a catalyst. | 10-18-2012 |
| 20120258923 | BIOACTIVITY COMPOSITION OF Reevesia formosana - A series cardenolide derivatives including structure of formula I from the root of | 10-11-2012 |
| 20120251482 | USE FOR IMPROVING 5-HT FUNCTION AND ENOS EXPRESSION OF KMUPS AMINE SALTS - The synthesized piperazium salt of KMUPs disclosed in the present invention is characterized by presented pharmaceutics having functions to improve 5-HT function and eNOS expression of KMUPS in lung diseases, such as proliferation, obliteration, pulmonary artery hypertension. The pharmaceutical composition for inhibiting monocrotaline (MCT)-induced proliferation of pulmonary artery includes an effective amount of a complex salt of formula (I): | 10-04-2012 |
| 20120245108 | METHOD OF MODULATING COMPLEMENT FACTOR B (CFB) EXPRESSION IN CELLS - The present invention relates to a method of modulating complement factor B (CFB) expression in cells, comprising administering an effective amount of tannic acid to the cells. This method can be applied in treating or prophylaxis of the disease, disorder or medical condition associated to complement factor B (CFB) expression. | 09-27-2012 |
| 20120215154 | SYNTHESIS OF 2-(4-AMINOPHENYL) BENZOTHIAZOLE DERIVATIVES AND USE THEREOF - The present invention provides a method of preparing a compound of formula 6 | 08-23-2012 |
| 20120215120 | NONINVASIVE CUTANEOUS BLOOD FLOW ASSESSMENT AS A RESPONSE PREDICTOR FOR VISIBLE LIGHT THERAPY ON SEGMENTAL VITILIGO - Visible light is a treatment option for Segmental Vitiligo (SV), and visible light-induced repigmentation is associated normalization of sympathetic. Currently it is difficult to predict individual patient's response to visible light therapy. Therefore, the present invention uses the Laser Doppler Flowmeter to serve as a response predictor for visible light on treating SV. The present invention recruited 14 Segmental Vitiligo patients for evaluating clinical information. FirstLaser Doppler Flowmeter was used to evaluate the cutaneous blood flow of SV lesion and contralateral normal skin, and then treated them with visible light irradiate, cold-stress, rewarmed, and recorded the change of skin blood flow, finally the patients received regular visible light treatment for 3 months, and patients have a sign of repigmentation after the treatment. | 08-23-2012 |
| 20120202064 | POLY(LACTIC-GLYCOLIC)ACID CROSS LINKED ALENDRONATE (PLGA-ALN) A SHORT TERM CONTROLLED RELEASE SYSTEM FOR STEM CELL DIFFERENTIATION AND DRUG DELIVERY - A short term controlled release composition which comprises poly(lactic-co-glycolic acid) cross-linked alendronate (PLGA-ALN) is provided. The PLGA-ALN is constructed into 3D scaffolds (PLGA-ALN-3D) with pores size of 150-300 μm and average porosity of 85%, or microspheres (PLGA-ALN-M) with 50-100 μm in diameter. The released alendronate concentration is in the range of 5×10 | 08-09-2012 |
| 20120196293 | METHOD AND KIT FOR IN VITRO DIAGNOSIS OF ATHEROSCLEROSIS - A method for in vitro diagnosis of atherosclerosis, comprising: (a) obtaining a sample from a subject; (b) determining expression levels of one or more microRNAs (miRNAs) as atherosclerotic biomarkers and an internal control RNA; (c) computing the relative expression levels of the one or more miRNAs as atherosclerotic biomarkers; (d) computing a prediction model with one or more variables, wherein the variable includes one or more relative expression levels of the one or more miRNAs as atherosclerotic biomarkers and one or more risk factors of atherosclerosis; and (e) computing a prediction probability by the prediction model, wherein the subject is diagnosed with atherosclerosis if the probability is more than 0.5 is presented. A kit for in vitro diagnosis of atherosclerosis or prognosis of atherosclerosis-inducing diseases is also presented. | 08-02-2012 |
| 20120196290 | METHOD FOR DIAGNOSING SPINAL MUSCULAR ATROPHY - A method for diagnosing spinal muscular atrophy is provided. The method includes providing a biological sample of a subject containing a nucleotide of SMN gene, amplifying SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a universal multiplex PCR using the nucleotide as a template and the primers to obtain fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8, labeling the fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a fluorescent primer to obtain fluorescence-labeled exon fragments, and analyzing the fluorescence-labeled exon fragments by a capillary electrophoresis under a optimized separation condition. If the SMN1/SMN2 ratios in exon 7 and 8 are different, it indicates that the subject is susceptible to spinal muscular atrophy. Additionally, if the peak of certain exon fragment appears crossed, it indicates an intragenic mutation in the exon. | 08-02-2012 |
| 20120190871 | TRITERPENOID COMPOSITION OF ANTRODIA CINNAMOMEA, PREPARATION AND ANALYSIS METHOD THEREOF - Disclosed are the isolation, purification and analysis of the triterpenoid compositions (including ergostane and lanostane) in the fruiting body of | 07-26-2012 |
| 20120190632 | ANTI-BACTERIAL INFECTION, INFLAMMATION, AND LEUKEMIA COMPOSITION AND USE THEREOF - A method of inhibiting the growth of Gram-positive bacteria comprising administering an effective amount of Tellimagrandin II, its pharmaceutically acceptable salt, enantiomer, isomer or tautomer to a subject is provided. The Gram-positive bacteria comprise methicillin-resistant | 07-26-2012 |
| 20120189652 | FREE RADICAL-INDUCED INTRACELLULAR DNA DAMAGE REDUCING REAGENT, MEDICAMENT OR HEALTH FOOD AND SKIN CARE PRODUCT OR COSMETIC, AND METHODS FOR PREPARING THE SAME - The invention provides a free radical-induced intracellular DNA damage reducing reagent, including: an effective amount of a | 07-26-2012 |
| 20120184570 | Theophylline Derivative Inhibits Osteoporosis - The theophylline derivative disclosed in the present invention is characterized by having the pharmaceutical functions of osteoporosis. The theophylline derivative protects against bone resorption and inflammatory mediator infiltration. | 07-19-2012 |
| 20120178945 | BENZENOID COMPOUNDS OF ANTRODIA CINNAMOMEA, PREPARATION AND ANALYSIS METHOD THEREOF - Disclosed are a method for preparing an n-hexane extract of the fruiting body of | 07-12-2012 |
| 20120177573 | METHODS FOR CONJUGATING NUCLEIC ACIDS WITH SMALL MOLECULES - A method for conjugating a nucleic acid with a molecule is provided. The method includes steps of (a) reacting the nucleic acid having a 5′-monophosphate with an activating agent in a first buffer to form a solution; (b) mixing an alcohol with the solution formed in the step (a) to obtain an intermediate; and (c) dissolving the intermediate in a second buffer containing an ethylenediaminetetraacetic acid (EDTA) and adding a nucleophile thereinto to react the intermediate with the nucleophile. | 07-12-2012 |
| 20120157626 | Hybrid Superparamagnetic Iron Oxide Nanoparticles And Polyethylenimine As A Magnetoplex For Gene Transfection - Disclosed are the nanoparticle and the method for the same, and the preparing method includes steps of mixing polyethylenimine (PEI) with the poly(acrylic acid)-bound iron oxide (PAAIO) to form a PEI-PAAIO polyelectrolyte complex (PEC) and mixing the PEI-PAAIO PEC with genetic material such as plasmid DNA to form the PEI-PAAIO/pDNA magnetic nanoparticle. The PEI-PAAIO/pDNA magnetoplex is highly water dispersible and suitable for long term storage, shows superparamagnetism, low cytotoxicity, high stability and nice transfection efficiency, and thus the PEI-PAAIO PEC can replace PEI as a non-viral gene vector. | 06-21-2012 |
| 20120141524 | ETHANOL EXTRACT OF ANTRODIA CAMPHORATA FOR INDUCING APOPTOSIS AND PREPARATION METHOD THEREOF - A preparation method for an ethanol extract of the fruiting body of | 06-07-2012 |
| 20120108604 | PROCESSES FOR PREPARING AMINE SALTS OF SILDENAFIL-ANALOGUES AND USE THEREOF - A series of amine salts including a structure of formula (I) and formula (III) have provided. In formula I or formula (III), R | 05-03-2012 |
| 20120100539 | METHOD FOR DETERMINING RISK FOR KIDNEY STONES DEVELOPING OR RECURRING AND METHOD FOR USING SINGLE-NUCLEOTIDE POLYMORPHISM RS12313273 AS BIOMARKER FOR DETERMINING DEVELOPMENT OR RECURRENCE OF KIDNEY STONE - The invention provides a method for determining a risk for kidney stones to develop in a subject, including: obtaining a biosample of the subject; detecting the presence of the single-nucleotide polymorphism rs12313273 (C/T) at position 30881 of the ORAI1 gene (SEQ ID No.: 1) in the biosample; and determining a risk for kidney stones to develop in the subject, wherein if the presence of a C allele of the single-nucleotide polymorphism rs12313273 (C/T) is detected, it indicates that the subject has an increased risk for kidney stones to develop. | 04-26-2012 |
| 20120095013 | USE OF KMUP-3 FOR MYOCARDIAL INFARCTION - A pharmaceutical composition for improving a cardiac function is provided. The pharmaceutical composition comprises an effective amount of an active component being one of a KMUP-3 compound and a salt thereof. | 04-19-2012 |
| 20120094985 | PHARMACEUTICAL COMPOSITIONS COMPRISING CHLOROPHENYL PIPERAZINE DERIVED COMPOUNDS AND USE OF THE COMPOUNDS IN PRODUCING MEDICAMENTS - The invention relates to a pharmaceutical composition for treating serotonergic neurotransmission related disease or condition, including an effective amount of a chlorophenylpiperazine derived compound of Formula (I), | 04-19-2012 |
| 20120088923 | METHOD FOR PREPARING A COUMARIN COMPOUND, CHROMENE COMPOUND, AND METHOD FOR PREPARING A CHROMENE COMPOUND - Disclosed herein is a method for preparing a coumarin compound of formula (F), in which R | 04-12-2012 |
| 20120045831 | POLY(LACTIC-GLYCOLIC)ACID CROSS LINKED ALENDRONATE (PLGA-ALN) A SHORT TERM CONTROLLED RELEASE SYSTEM FOR STEM CELL DIFFERENTIATION AND DRUG DELIVERY - The present invention relates to a bisphosphonates and synthetic polymeric carriers to form a sustained release system. The present invention also provides a method for preparing a sustained release system, comprising activation of the synthetic polymeric carriers and the cross linking reaction. The present invention further provides methods for enhancing stem cell differentiation into osteogenic lineage and chondrogenic lineage, which comprise culturing a population of stem cells in specific micro-environments. | 02-23-2012 |
| 20120028827 | METHOD FOR DETERMINING A RISK, FOR A SUBJECT, OF SUFFERING FROM ATOPIC DERMATITIS OR SEVERITY OF ATOPIC DERMATITIS FOR A SUBJECT SUFFERING FROM ATOPIC DERMATITIS AND METHOD FOR USING A SINGLE-NUCLEOTIDE POLYMORPHISM RS12313273 AS A BIOMARKER FOR DETERMINING THE DEVELOPMENT OR SEVERITY OF ATOPIC DERMATITIS - The invention provides a method for determining a risk, for a subject, of suffering from atopic dermatitis, including: obtaining a biosample of the subject; detecting the presence of the single-nucleotide polymorphism rs12313273 (C/T) at position 30881 of the ORAI1 gene (SEQ ID No.: 1) in the biosample; and determining the risk, for the subject, of suffering from atopic dermatitis, wherein the presence of a C allele or genotype CC of the single-nucleotide polymorphism rs12313273 (C/T) indicates that the subject is at increased risk for suffering from atopic dermatitis. | 02-02-2012 |
| 20120015380 | ANTI-POLYETHYLENE GLYCOL ANTIBODY EXPRESSING CELL QUANTIFY ANY FREE POLYETHYLENE GLYCOL AND POLYETHYLENE GLYCOL-DERIVATIZED MOLECULES - In this invention, anti-PEG antibodies or anti-methoxyl-PEG (anti-CH | 01-19-2012 |
| 20110318835 | Implant Surface Treatment Method Having Tissues Integrated - The present disclosure uses different kinds of surface treatment processes on titanium-made dental implants. The growth and attachment conditions of bone cells (MC3T3-E), fibroblasts(NIH 3T3) and epidermal cells (XB-2) on the metal surface of titanium slices with different surface treatments are observed. Tetra-calcium phosphate is used to perform secondary sand-blasting process to clean up the metal surface and provide calcium ions for osteoblastoma physiology. Thus, by adjusting the cells adhesive and proliferative abilities, the success rate of the clinical applications in dental implant is improved. | 12-29-2011 |
| 20110318331 | Nanoparticles and Use Thereof - A novel nanoparticle and use thereof were provided in the present invention. In particular, the nanoparticle is used for delivering therapeutic component, such as oligonucleotide and hydrophobic drug. | 12-29-2011 |
| 20110312885 | CONTROLLED RELEASE SYSTEM AND MANUFACTURING METHOD THEREOF - A controlled release system and manufacturing method is provided. The method comprises providing a first aqueous solution containing a hydrophilic drug and an alkaline agent, providing an organic solution containing a hydrophobic molecule, providing a second aqueous solution containing a hydrophilic surfactant, mixing the first hydrophilic solution with the organic solution to form a first emulsion, and mixing the first emulsion with a second aqueous solution to form a second emulsion containing delayed-release microsphere. | 12-22-2011 |
| 20110306775 | SYNTHESIS AND BIOLOGICAL EVALUATION OF 2',5'-DIMETHOXYCHALCONE DERIVATIVES AS MICROTUBULE-TARGETED ANTICANCER AGENTS - Disclosed are a serious of 2′,5′-dimethoxychalcone derivatives for treating cancer, wherein 2,5-dimethoxyacetophenone and methyl 4-formylbenzoate are condensed to form 4-carboxyl-2′,5′-dimethoxychalcone (compound 1), which is further reacted with alkyl halides or amines to synthesize the chalcone derivatives of compounds 2-17. In addition, 2,5-dimethoxyacetophenone is reacted with 5-formyl-2-thiophenecarboxylic acid to form compound 18 (3-(3-thiophene)carboxyl-1-(2,5-dimethoxyphenyl)prop-2-en-1-one). The synthesized 2′,5′-dimethoxychalcone derivatives can be acted as microtubule-targeted tubulin-polymerizing agents. | 12-15-2011 |
| 20110305766 | Method for Controlled Release of Parathyroid Hormone from Encapsulated Poly(Lactic-Glycolic)Acid Microspheres - The present invention provides a method for producing a controlled release microsphere with mean average size greater than 50 μm, comprising preparing a water-in-oil (w/o) emulsion comprising an inner aqueous layer containing a pharmaceutically effective amount of a biologically active polypeptide with activity similar to parathyroid hormone, and an oil layer containing a polymer substance of poly (lactic-co-glycolic acid) (PLGA), then adding the w/o emulsion into aqueous polyvinyl alcohol (PVA) solution to form a water-in-oil-in-water (w/o/w) double emulsion and then desorbing the solvent in the oil layer. The present invention also provides a controlled release microsphere prepared by the method and use thereof. | 12-15-2011 |
| 20110248417 | METHOD FOR PREPARING COMPOSITION COMPRISING POROUS CERAMIC WITH THERMO-RESPONSE HYDROGEL - The present invention provides a method for preparing a composition comprising porous ceramic, comprising the following steps: (a) synthesizing poly(N-isopropylacrylamide-co-methacrylic acid) (p(NIPAAM-MAA)) or similar thermo-response compound thereof; (b)mixing a dispersant with hydroxyapatite or calcium phosphate salt; (c) mixing the p(NIPAAM-MAA) of the step (a) or similar thermo-response compound thereof with water to obtain a hydrogel solution; (d) mixing the hydrogel solution of the step (c) and product of the step (b) to produce a mixture; (e) adding macromolecular particles to the mixture of the step (d) and stirring to produce a slurry; (f) filling the slurry of the step (e) into a template slot; and disposing the template slot filling with the slurry of the step (f) on a crucible, then proceeding high temperature sinter in a furnace to form the composition comprising porous ceramic. | 10-13-2011 |
| 20110244463 | METHOD FOR COLUMBIDAE GENDER IDENTIFICATION, NUCLEOTIDE SEQUENCE FOR COLUMBIDAE GENDER AND NUCLEOTIDE PRIMER PAIR FOR COLUMBIDAE GENDER - The invention provides a method for Columbidae gender identification including: providing a DNA sample of a bird belonging to the Columbidae family; performing a polymerase chain reaction to the DNA sample with a first primer pair of a first primer designed within the region of the SEQ ID. NO.: 9 or a complementary sequence thereof and a P2 primer (SEQ ID. NO: 1) or a complementary sequence thereof, and a second primer pair of a second primer designed within the region of the SEQ ID NO.: 10 or a complementary sequence thereof and a P2 primer (SEQ ID. NO: 1) or a complementary sequence thereof; and determining gender by performing a melting curve analysis to a product from the polymerase chain reaction, wherein the result showing two peaks indicate a female gender and showing one peak indicate a male gender. | 10-06-2011 |
| 20110212194 | Composition for Inhibiting Melanogenesis and Use Thereof - The present invention provides a | 09-01-2011 |
| 20110201618 | KMUPS INHIBITING PROLIFERATION AND OBLITERATION OF PULMONARY ARTERY - An obstructive pulmonary disease inhibiting pharmaceutical composition is provided. The obstructive pulmonary disease inhibiting pharmaceutical composition includes: | 08-18-2011 |
| 20110196029 | COMPOSITION FOR TREATING INFLUENZA A (H1N1) VIRUS AND A PREPARATION METHOD THEREFOR - New pharmaceutical compositions extracted from | 08-11-2011 |
| 20110190388 | URSOLIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF - Several ursolic acid derivatives and pharmaceutical compositions thereof are provided. The ursolic acid derivatives and the pharmaceutical compositions thereof have at least one of an anticancer and an anti-inflammatory effects. A method for increasing a reactive oxygen species in a cell is also provided. The method comprises a step of providing the cell with a pharmaceutical composition including an ursolic acid derivative. | 08-04-2011 |
| 20110159127 | EXTRACT OF TOONA SINENSIS FROM SUPERCRITICAL FLUID EXTRACTION FOR TREATING DIABETES AND METABOLIC DISEASES, THE PREPARATION METHOD AND THE USE THEREOF | 06-30-2011 |
| 20110142913 | COMPOSITION AND METHOD FOR TREATING ATHEROSCLEROSIS, METHOD FOR DETERMINING IF A SUBJECT HAS ATHEROSCLEROSIS AND METHOD OF SCREENING AN ANTI-ATHEROSCLEROTIC DRUG - The invention provides a method for determining if a subject has atherosclerosis, including: determining an endogenous microRNA-195 expression level of a subject suspected of having atherosclerosis; and comparing the endogenous microRNA-195 expression level of the subject with an endogenous microRNA-195 expression level of a normal group, wherein an increase in the endogenous microRNA-195 expression level of the subject as compared to the endogenous microRNA-195 expression level of the normal group indicates that the subject has atherosclerosis. | 06-16-2011 |
| 20110136767 | PROCESSES FOR PREPARING PIPERAZINIUM SALTS OF KMUP AND USE THEREOF - A series of monoquarternary piperazium salts including a structure of a formula I or II are provided. In formula I or II, R | 06-09-2011 |
| 20110129838 | USING GENETIC POLYMORPHISMS OF THE BICD1 GENE AS A METHOD FOR DETERMINING A RISK OF DEVELOPING MYOPIA - A method and kit for determining an increased risk of developing myopia in a subject is provided by detecting an SNP in the BICD1 gene. The SNP is selected from a group consisting of rs10844126 (A/C), rs1151029 (A/T), rs2650122 (C/T), rs10771923 (A/G), rs1151009 (T/C), rs2125173 (A/G) and rs161959 (C/G). When the presence of the risk allele associated with myopia is detected at the SNP, the subject is determined in an increased risk of developing myopia. | 06-02-2011 |
| 20110124655 | KMUP-1 CAPABLE OF TREATING HYPERTENSION - A cardiomyocyte hypertrophy inhibiting pharmaceutical composition is provided. The composition comprises an effective amount of a compound of 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine; and a pharmaceutically acceptable carrier. | 05-26-2011 |
| 20110098219 | System for Curing Hepatic Cancer with Leptin - The present invention cures hepatic cancer by MPA with the help of leptin. A therapeutic drug of MPA combined with leptin is applied to a liver cancer patient. Or, MPA can be directly applied to a patient having a high leptin expression. Or, if a patient has a low leptin expression, MPA is applied to the patient after leptin expression is increased. Hence, expression of leptin can be taken as a predictive factor and a prognostic factor of treatment effect on curing the patient with MPA. | 04-28-2011 |
| 20110085987 | FOLIC ACID-MEDIATED MAGNETIC NANOPARTICLE CLUSTERS FOR COMBINED TARGETING, DIAGNOSIS, AND THERAPY APPLICATIONS - The preparation method of the magnetic nanoparticle (MNP) includes steps of: (a) reacting folic acid (FA) with Pluronic F127 (PF127) to form FA-PF127; (b) reacting poly(acrylic acid) (PAA) with FeCl3 to form PAA-bound iron oxide (PAAIO); and (c) reacting FA-PF127 with PAAIO via N-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDAC) mediation to form FA-PF127-PAAIO. FA-PF127-PAAIO is nontoxic and shows the superparamagnetic property at room temperature. The Nile red-loaded FA-PF127-PAAIO can be performed as the chemotherapy agent and the contrast agent on magnetic resonance (MR) imaging. | 04-14-2011 |
| 20110064651 | RECOMBINANT NUCLEOTIDE SEQUENCE, CELL OR VECTOR CONTAINING THE SAME AND METHOD FOR USING CELL CONTAINING THE SAME TO ENCODE ANTI-POLYETHYLENE GLYCOL MONOCLONAL ANTIBODIES - The invention provides a recombinant nucleotide sequence, including the sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, wherein the recombinant nucleotide sequence encodes an anti-polyethylene glycol recombinant single chain membrane antibody. | 03-17-2011 |
| 20110052691 | Sustained Release Systems and Preparation Method Thereof - The present invention relates to a hydrophilic drug and β-tricalcium phosphate (β-TCP) coating on a surface area of biopolymer matrix to form a sustained release system. The present invention also provides a method for preparing a sustained release system, comprising providing a surface are of biopolymer matrix coated with a hydrophilic drug and β-TCP. | 03-03-2011 |
| 20110039922 | 18beta-GLYCYRRHETINIC ACID DERIVATIVES AND SYNTHETIC METHOD THEREOF - The present invention provides a chemical compound having the structure being one selected from a group consisting of | 02-17-2011 |
| 20110033861 | METHOD FOR DIAGNOSING SPINAL MUSCULAR ATROPHY - A method for diagnosing spinal muscular atrophy is provided. The method includes providing a biological sample of a subject containing a nucleotide of SMN gene, amplifying SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a universal multiplex PCR using the nucleotide as a template and the primers to obtain fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8, labeling the fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a fluorescent primer to obtain fluorescence-labeled exon fragments, and analyzing the fluorescence-labeled exon fragments by a capillary electrophoresis. If the SMN1/SMN2 ratios in exon 7 and 8 are different, it indicates that the subject is susceptible to spinal muscular atrophy. Additionally, if the peak of certain exon fragment appears crossed, it indicates an intragenic mutation in the exon. | 02-10-2011 |
| 20100317671 | XANTHINE-BASED CYCLIC GMP-ENHANCING RHO-KINASE INHIBITOR INHIBITS PHYSIOLOGICAL ACTIVITIES OF LUNG EPITHELIAL CELL LINE - A pharmaceutical composition for a treatment of an interstitial lung disease is provided. The pharmaceutical composition comprises an effective amount of an active component being one selected from a group consisting of a KMUP compound, a KMUP monoquaternary ammonium salt and a KMUP monoquaternary ammonium complex salt, wherein the KMUP monoquaternary ammonium complex salt is synthesized by the KMUP compound and a carboxylic acid derivative of one selected from a group consisting of a statin, a non-steroid anti-inflammatory (NSAIDs) and an anti-asthmatic drug. | 12-16-2010 |
| 20100313791 | CALCIUM PHOSPHATE BONE CEMENT, PRECURSOR THEREOF AND FABRICATION METHOD THEREOF - The invention provides a calcium phosphate bone cement, a precursor and a fabrication method thereof. The fabrication method comprises: (a) dissolving a calcium phosphate with a low Ca/P atomic ratio in an acid solution, wherein the Ca/P atomic ratio is less than 1.33; (b) adding a calcium phosphate compound into the acid solution to obtain a reaction solution; (c) allowing the reaction solution to stand to grow nanocrystallites on surfaces of the calcium phosphate with low Ca/P atomic ratio; (d) filtering and drying the solution of step (c) to obtain a calcium phosphate powder with low Ca/P atomic ratio having nanocrystallites on the surface; and (e) mixing the powder of step (d) and a calcium phosphate powder with a high Ca/P atomic ratio. | 12-16-2010 |
| 20100298582 | Intermediate Compounds and Processes for the Preparation of 7-benzyloxy-3-(4-methoxyphenyl)-2H-1-benzopyran - Disclosed herein is a compound of formula (I): | 11-25-2010 |
| 20100298581 | Processes for Preparing Isoflavonoids using 7-benzyloxy-3-(4-methoxyphenyl)-2H-1-benzopyran as a Starting Material - Disclosed herein are processes for the preparation of isoflavonoids, in particular haginin E, equol, daidzein, formononetin and the like, in which 7-benzyloxy-3-(4-methoxyphenyl)-2H-1-benzopyran is used as a common starting material. | 11-25-2010 |
| 20100280041 | RHOKINASE-DEPENDENT INHIBITION ACTIVITY ON PULMONARY ARTERY ENDOTHELIUM DYSFUNCTION, MEDIAL WALL THICKNESS AND VASCULAR OBSTRUCTION OF PULMODIL AND PULMODIL-1 - A pharmaceutical composition for treating one of a cardiovascular disease and a pulmonary artery disease, comprising one of a first compound having a Formula I and a second compound having a Formula II. | 11-04-2010 |
| 20100280040 | SYNTHESIS AND PHARMACOKINETIC ACTIVITIES OF PULMODIL AND PULMODIL-1, TWO CHLOROPHENYLPIPERAZINE SALT DERIVATIVES - A compound including a salt derivative of the chlorophenylpiperazine moiety is provided, wherein the chlorophenylpiperazine moiety is derived from the reaction of a xanthine and a piperazine. The salt derivative thereof is non-toxic to the tracheal smooth muscle cells (TSMCs) and can be intravenously-, orally- or sublingually-dosed into the mammals. | 11-04-2010 |
| 20100280039 | PHARMACEUTICAL COMPOSITIONS COMPRISING CHLOROPHENYL PIPERAZINE DERIVED COMPOUNDS AND USE OF THE COMPOUNDS IN PRODUCING MEDICAMENTS - The invention relates to a pharmaceutical composition for treating serotonergic neurotransmission related disease or condition, including an effective amount of a chlorophenylpiperazine derived compound of Formula (I), | 11-04-2010 |
| 20100248253 | METHOD AND KIT FOR ASSESSING RISK OF GOUT AND HYPERURICEMIA - A method for assessing a risk of suffering from a gout of a subject is provided. The method includes steps of obtaining a nucleotide sample from the subject; determining a genetic polymorphism of one of a Urate transporter 1 (URAT1) gene and an alpha-kinase 1 (ALPK1) gene in the nucleotide sample, wherein the genetic polymorphism is associated with an occurrence of the gout; and comparing the genetic polymorphism with a predetermined genetic polymorphism so as to assess the risk of suffering from the gout of the subject. | 09-30-2010 |
| 20100233688 | METHOD FOR DIAGNOSING SPINAL MUSCULAR ATROPHY - A method for diagnosing spinal muscular atrophy is provided. The method includes providing a biological sample of a subject containing a nucleotide of SMN gene, amplifying SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a universal multiplex PCR using the nucleotide as a template and the primers to obtain fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8, labeling the fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a fluorescent primer to obtain fluorescence-labeled exon fragments, and analyzing the fluorescence-labeled exon fragments by a capillary electrophoresis. If the SMN1/SMN2 ratios in exon 7 and 8 are different, it indicates that the subject is susceptible to spinal muscular atrophy. Additionally, if the peak of certain exon fragment appears crossed, it indicates an intragenic mutation in the exon. | 09-16-2010 |
| 20100227404 | WATER EXTRACT OF ANTRODIA CAMPHORATA FOR IMMUNOSTIMULATORY EFFECT AND PREPARATION METHOD THEREOF - A preparation method for a water extract of the fruiting body of | 09-09-2010 |
| 20100210869 | ETHANOL EXTRACT OF ANTRODIA CAMPHORATA FOR INDUCING APOPTOSIS AND PREPARATION METHOD THEREOF - A preparation method for an ethanol extract of the fruiting body of | 08-19-2010 |
| 20100160229 | TREATMENT OF EARLY-STAGE OSTEOARTHRITIS - A method for treating early-stage osteoarthritis in an animal is provided. The method comprises delivery of a therapeutically effective amount of a parathyroid hormone (PTH) or a PTH derived substance to an affected joint cavity of the patient. Methods for inhibiting articular chondrocytes apoptosis and for inhibiting a degenerative process of articular chondrocytes in an afflicted animal are also provided. | 06-24-2010 |
| 20100159575 | QUANTITATIVE SAMPLER OF PATHOGENS IN EXHALED AIR - A quantitative sampler of pathogens in exhaled air is provided. The quantitative sampler includes an air inputting pipe for a sampled individual to blow exhaled air; a check valve unit for preventing the exhaled air from reversely flowing; an aerosol filtering unit having an aerosol filtering material for collecting aerosol particles in the exhaled air; and an air flow meter for measuring if total accumulated volume of the exhaled air reaches a predetermined sampling volume defined as a concentration denominator of exhaled pathogens. The quantitative sampler can be used to collect the aerosol particles, and then moves the aerosol filtering material out of the aerosol filtering unit followed by separating genetic substances in the aerosol particles from the aerosol filter, so that a real-time qPCR can be reacted by using the genetic substances for obtaining a quantitative concentration of the exhaled pathogens. | 06-24-2010 |
| 20100150997 | TREATMENT OF ARTHRITIS - A method for treating and/or inhibiting arthritis is provided. The method includes administering an effective amount of a composition including a parathyroid hormone and a pharmaceutically acceptable carrier or salt to a subject with arthritis. Additionally, a method for inhibiting and/or rescuing terminal differentiation of cells is also provided. | 06-17-2010 |
| 20100035255 | METHOD AND KIT FOR ASSESSING RISK OF GOUT AND HYPERURICEMIA - A method for assessing a risk of suffering from a gout of a subject is provided. The method includes steps of obtaining a nucleotide sample from the subject; determining a genetic polymorphism of one of a Urate transporter 1 (URAT1) gene and an alpha-kinase 1 (ALPK1) gene in the nucleotide sample, wherein the genetic polymorphism is associated with an occurrence of the gout; and comparing the genetic polymorphism with a predetermined genetic polymorphism so as to assess the risk of suffering from the gout of the subject. | 02-11-2010 |
| 20100022552 | KMUP-1 CAPABLE OF TREATING HYPERTENSION - A method for treating a spontaneous hypertension or a cardiomyocyte hypertrophy is provided. The method comprises a step of administering to a mammal a therapeutically effective amount of a compound of 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethyl xanthine. | 01-28-2010 |
| 20100021889 | USING GENETIC POLYMORPHISMS OF THE BICD1 GENE AS A METHOD FOR DIAGNOSING AND TREATING MYOPIA - Using the BICD | 01-28-2010 |
| 20100016329 | XANTHINE-BASED CYCLIC GMP-ENHANCING RHO-KINASE INHIBITOR INHIBITS PHYSIOLOGICAL ACTIVITIES OF LUNG EPITHELIAL CELL LINE - The present invention provides a pharmaceutical composition including a compound of 7-[2-[4-(2-chlorophenyl)piperazinyl]-ethyl]-1,3-dimethylxanthine (KMUP-1), wherein the compound is a Rho-kinase inhibitor, and the pharmaceutical composition inhibits a physiological activity of a lung epithelial cell. | 01-21-2010 |
| 20100015645 | IL-8 AS BIOMARKER FOR THE DETECTION OF UROLITHIASIS - Disclosed herein is a method for the detection or preliminary screening of urolithiasis, comprising: detecting the IL-8 level and the creatinine level in a urine sample taken from a human subject suspected to have urolithiasis; obtaining a creatinine-normalized IL-8 level in the urine sample by normalizing the detected IL-8 level to the detected creatinine level; and comparing the creatinine-normalized IL-8 level in the urine sample with a predetermined standard; wherein an elevation of the creatinine-normalized IL-8 level in the urine sample as compared to the predetermined standard is indicative of urolithiasis. | 01-21-2010 |
| 20090306093 | METHOD FOR TREATING PATIENT HAVING BENIGN PROSTATE HYPERPLASIA - A method for treating a patient having lower urinary tract symptoms is provided. The method comprises a step of administering to the patient a therapeutically effective amount of one selected from a group consisting of a treating compound of 7-[2-[4-(2-Chlorobenzene)piperazinyl]ethyl]-1,3-dimethyl xanthine, a salt of the treating compound, a solvate of the treating compound and a combination thereof, wherein the compound has an effect on treating the benign prostate hyperplasia via a mechanism selected from a group consisting of an activation of PKG pathway, a blockage of an adrenoceptor, an opening of a potassium channel and an inhibition of PDE activity. | 12-10-2009 |
| 20090298846 | Indolo[3,2-c]quinoline Compounds - Indolo[3,2-c]quinoline compounds of formula (I) shown below. Each variable in this formula is defined herein. These compounds can be used to inhibit both growth of cancer cells and activity of telomerase. | 12-03-2009 |
| 20090209560 | ANTI-INFLAMMATION ACTIVITY OF NEWLY SYNTHESIZED XANTHINE DERIVATIVES KMUP-1 AND KMUP-3 - An anti-inflammation substrate for decreasing the proinflammation induced by the cytokines and inhibiting the lung function degeneration is provided. The anti-inflammation substrate includes one selected from the group consisting of a 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine, a 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine, a respective pharmaceutical acceptable salt thereof, and a combination thereof. | 08-20-2009 |
| 20090170200 | STEM CELL MEDIUM - A medium for culturing stem cell. The stem cell medium of the invention comprises a fetal bovine serum, one or plurality of amino acid, one or plurality of vitamin, one or plurality of growth factor, one or plurality of inorganic salt, one or plurality of antioxidant, wherein the stem cell medium has a calcium concentration of less than about 1.8 mM, and the fetal bovine serum is present in an amount of less than about 10% by volume of the medium. The stem cell medium of the invention can maintain the proliferative and self-renewal capacity of the stem cells and keep stem cells at a steady stage. | 07-02-2009 |
| 20090170177 | STEM CELL TRANSFECTION METHOD - Stem cell transfection method. The stem cell infection method of the invention comprises providing a stem cell; positioning the stem cell at a buffer, wherein the buffer contains a foreign material; electroporating the stem cell in the buffer; and culturing the stem cell. | 07-02-2009 |
| 20090169658 | TOONA SINENSIS EXTRACT FOR SUPPRESSING PROLIFERATION AND INDUCING APOPTOSIS OF OSTEOSARCOMA CELLS - extract for suppressing the proliferation and inducing apoptosis of osteosarcoma, but not normal human osterblasts. The extraction process comprises: extracting | 07-02-2009 |
| 20090111987 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same - Disclosed herein are novel imino-indeno[1,2-c]quinoline derivatives of formula (I): | 04-30-2009 |
| 20090088412 | COMPOSITION FOR TREATING CANCER CELLS AND PREPARATION METHOD THEREOF - A composition for treating cancer cells and a preparation method therefore is provided. The composition includes novel withanolide compounds derived from a Solanaceae plant, which the novel withanolide compounds have the cytotoxicity to the cancer cells. | 04-02-2009 |
| 20090081677 | METHOD FOR GENDER IDENTIFICATION OF EAGLES WITH PROBE-BASED REAL-TIME PCR AND THE SEQUENCES USED FOR GENDER IDENTIFICATION OF EAGLES - A method for gender identification of eagles includes: providing a DNA of an eagle; performing a probe-based real-time PCR using the DNA as a template, a universal primer pair P2/P8 as a primer pair and a first probe and a second probe as probes, wherein the 5′ ends of the first probe and the second probe are labeled with a first fluorescent dye and a second fluorescent dye, respectively, and the first probe is a sequence with about 15-38 nucleotides in length of SEQ ID No. 1 and the second probe is a sequence with about 15-44 nucleotides in length of SEQ ID No. 2; and analyzing a result of the PCR, wherein if the result is positive for both the first and the second fluorescent dye, the eagle is a female, and if the result is positive for only the first fluorescent dye, the eagle is a male. | 03-26-2009 |
| 20090054516 | COMPOSITION FOR TREATING CANCER CELLS AND SYNTHETIC METHOD FOR THE SAME - A pharmaceutical composition having a cytotoxic effect to a cancer cell and a method for the same are provided. The pharmaceutical composition comprises a flavonoid compound having at least one of the following formulas: | 02-26-2009 |
| 20080312249 | KMUP-1 CAPABLE OF TREATING HYPERTENSION - A pharmaceutical composition for treating the hypertension is provided. The pharmaceutical composition comprises a chemical compound of 7-[2-[4-(2-Chlorobenzene)piperazinyl]ethyl]-1,3-dimethyl xanthine and one of a pharmaceutical acceptable salt thereof and a solvate thereof, wherein the chemical compound treats the hypertension by cGMP-dependent inhibition on Rho kinase. | 12-18-2008 |
